The ruling removes a material overhang on Vabysmo's global commercial prospects. Monitor for any appeal by Novartis within 30 days; if none, the decision is final and Genentech's Vabysmo revenue stream is fully protected.
Price Chart
Executive Summary
The D.C. District Court granted Genentech's petition to enforce a foreign arbitration award against Novartis, confirming that Vabysmo (faricimab) is not a licensed product under their collaboration agreements and ordering Novartis to pay ~$17.8M in costs plus interest. This removes uncertainty around Vabysmo's commercial freedom and affirms Genentech's right to market the drug globally without royalty obligations to Novartis.
Court Ruling Details
Key Facts
- Court entered final judgment enforcing the April 2025 arbitration award in full
- Vabysmo (faricimab) declared not a Licensed Product under the License and Collaboration Agreements with Novartis
- Novartis ordered to pay $584,250 in arbitrator fees and $17,255,928.62 in legal costs, plus 9% annual interest
- Novartis's claim that Genentech breached LCAs by seeking regulatory approval of Vabysmo outside the U.S. was denied
- Ruling is final and immediately enforceable under 9 U.S.C. § 207
Financial Impact
~$17.8M in awarded costs plus interest; more significantly, Genentech retains full economics on Vabysmo (faricimab) without royalty obligations to Novartis
Risk Factors
- Novartis may appeal the enforcement order to the D.C. Circuit, though likelihood is low given the finality of the arbitration award
- Potential for collateral litigation in other jurisdictions where Novartis may challenge enforcement
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-8dba9aa8b4-RHHBY |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | Court Ruling | — | awaiting T+5 | — | — |
Oct 13, 2026 13d ago | Court Ruling | $55.69 $59.11 | ▲ +6.14% | ▲ +5.69% | $61.17 (+9.84%) |
Aug 14, 2026 10w ago | Court Ruling | $54.61 $57.47 | ▲ +5.24% | ▲ +6.43% | $61.17 (+12.01%) |
Jul 30, 2026 12w ago | Court Ruling | $54.67 $57.26 | ▲ +4.74% | ▲ +1.23% | $61.17 (+11.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers